“The average biotech bull market has been good for 566% gains in under three years.” says Dr. Steve Sjuggerud. In Daily Wealth, he adds, “Biotech looks incredibly bullish right now.”

“Biotech giant Genentech shot up as big pharmaceutical company Roche offered to buy it out completely.

“If $100 billion Genentech can sell to a ‘Big Pharma’ company, then every biotech stock has to be in play right now. And biotech just went from the back pages to the front pages. This is when you want to be a buyer.

“Biotech has been the quiet performer this year. Oil, bank stocks, and real estate have garnered all the headlines. But biotech has been the stealth winner. Shares of the S&P Biotech Index Fund – have quietly hit new highs.

“Consider the Rydex Biotech Fund, for example. Back in 2000, during the last biotech peak, this fund had $1.4 billion invested. Then, for eight years, biotech stocks did nothing.

“Assets in the fund absolutely collapsed, bottoming earlier this year at around $60 million – that’s more than a 95% fall in assets. But, what’s this? In just the last few weeks, assets in the fund have more than doubled! Investors are quietly creeping in.

“Biotechs are an exceptional bargain now, when you size them up on simple, traditional measures of biotech value (like price-to-sales, for instance). In short, while the companies’ stock prices have done nothing in eight years… their businesses have kept growing, so shares are a great value.

“If you catch just one biotech bull market, you’ll never have to work again. And now, we have our catalyst to get biotech from the back pages of the ‘Money’ section to the front – the Genentech offer from Roche.

“One simple way to buy into biotech is through the S&P Biotech ETF, XBI. But no matter how you do it, now is finally the time. Biotech’s next big bull market should be starting right now.”

Track this pick at:

http://trackthepros.com/categories.php?category_id=1384